Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

63850 1504871583HCLSReviewHongKongSeptember2017.pdf
Energy Boardroom

Supreme Court to hear Teva's Copaxone appeal

31.03.2014 / Fierce Pharma

The Supreme Court has agreed to hear an appeal of a lower court's decision to invalidate Teva's Copaxone patent, which if restored will shield the drug until September 2015. The decision may, in the least, leave competitors wary of proceeding with generics, giving Teva more time to convert patients to a new, long-acting version of the treatment.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: